Explosive Growth Expected: Oral Solid Dosage Contract Manufacturing Market on the Rise by 2034
The global Oral Solid Dosage (OSD) Contract Manufacturing Market is undergoing significant expansion, propelled by the rising trend of pharmaceutical outsourcing, the growing prevalence of chronic diseases, and the increasing need for cost-effective and scalable manufacturing solutions. With drug manufacturers prioritizing speed-to-market and cost containment, the demand for contract development and manufacturing organizations (CDMOs) specializing in OSD forms—such as tablets, capsules, powders, and granules—is surging across the globe.
Market Overview
Global Oral Solid Dosage Contract Manufacturing Market size and share is currently valued at USD 37.82 billion in 2024 and is anticipated to generate an estimated revenue of USD 57.02 billion by 2032 , according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 5.3% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2024 - 2032
OSDs remain the most preferred form of drug delivery owing to their ease of administration, longer shelf life, and low manufacturing costs. In recent years, CDMOs have advanced their capabilities in formulation development, scale-up, and packaging solutions, thereby supporting pharmaceutical and biotech companies in achieving faster time-to-market with improved product quality.
Market Segmentation
The Oral Solid Dosage Contract Manufacturing Market can be segmented based on dosage form, service type, and end-user.
By Dosage Form
Tablets: Represent the largest segment due to their high patient compliance, cost-effectiveness, and ease of mass production.
Capsules: Gaining traction due to improved bioavailability and suitability for both solid and liquid APIs.
Powders and Granules: Frequently used in pediatric and geriatric formulations, with demand growing in niche therapeutic areas.
By Service Type
Manufacturing Services: Includes bulk production of OSDs. Demand is increasing due to pharmaceutical outsourcing, especially for generic drugs and over-the-counter (OTC) products.
Formulation Development: A rapidly growing segment as companies seek innovative and modified-release formulations for enhanced drug delivery.
Packaging and Labeling: Includes blistering, bottling, and serialization services, especially important for clinical trial and global distribution needs.
By End-User
Pharmaceutical Companies: Both branded and generic firms use CDMOs for cost efficiency and regulatory expertise.
Biotechnology Firms: Often partner with CDMOs during early-stage development through commercialization.
Contract Research Organizations (CROs): Collaborate with CDMOs to offer integrated drug development solutions.
Regional Analysis
The global market shows regional variance in growth drivers, investment trends, and regulatory landscapes.
North America
North America continues to dominate the global OSD contract manufacturing market, driven by the strong presence of leading pharmaceutical companies, high healthcare spending, and a favorable regulatory framework. The United States, in particular, leads the region due to significant investments in drug development and the presence of major CDMOs with advanced capabilities in tablet manufacturing and regulatory compliance.
Europe
Europe is the second-largest market, with the UK, Germany, and France emerging as prominent hubs. European pharma companies increasingly outsource to CDMOs to meet stringent regulatory guidelines and reduce time-to-market. The region also benefits from a well-established infrastructure and government incentives for pharmaceutical innovation.
Asia Pacific
Asia Pacific is projected to exhibit the fastest growth through 2030. Countries like India and China are becoming global centers for pharmaceutical outsourcing due to cost advantages, skilled labor, and expanding production capabilities. Regulatory harmonization and rising investment in healthcare infrastructure also contribute to regional growth.
Latin America and Middle East & Africa
These regions are still emerging but show increasing activity in the CDMO space, especially as global companies look to diversify their supply chains. Brazil, Mexico, South Africa, and Saudi Arabia are key markets to watch due to growing generic drug demand and public health initiatives.
Browse Full Insights:
Key Companies
The global OSD contract manufacturing landscape is moderately fragmented, with numerous CDMOs offering specialized services to pharmaceutical and biotech firms. The market includes both global leaders and regional players, each contributing unique capabilities in formulation development, scalability, and regulatory adherence.
Catalent Inc.
Catalent is a global CDMO leader, offering a comprehensive suite of OSD services, including advanced formulation development, controlled-release technologies, and clinical trial manufacturing. The company has a strong presence in North America, Europe, and Asia.
Lonza Group AG
Lonza’s pharma and biotech segment is renowned for its expertise in regulatory compliance, complex drug delivery systems, and late-stage clinical production. Lonza continues to expand its OSD manufacturing capacity through strategic acquisitions and partnerships.
Thermo Fisher Scientific (Patheon)
Thermo Fisher provides integrated pharmaceutical services, including OSD manufacturing, packaging, and logistics. The company’s global network ensures scalable, end-to-end production solutions tailored to client needs.
Recipharm AB
Headquartered in Sweden, Recipharm is a key European CDMO offering high-capacity OSD manufacturing and formulation development services. The company supports both large and niche pharma firms across multiple therapeutic areas.
Piramal Pharma Solutions
Piramal operates across North America, India, and the UK, offering OSD services with a focus on high-potency APIs and sustained-release formulations. Their flexible model is particularly attractive to small and mid-sized companies.
Other noteworthy companies include:
Aenova Group – Offers integrated solutions with strong presence in Europe.
Almac Group – Specializes in clinical trial manufacturing and niche formulations.
Strides Pharma Science – India-based CDMO with a global footprint and specialization in generic OSDs.
DPT Laboratories – Known for its focus on sterile and non-sterile pharmaceutical manufacturing.
Market Trends and Future Outlook
Increased Use of Modified-Release Technologies
The push for improved patient adherence is driving demand for OSDs with sustained-release and targeted-delivery mechanisms. CDMOs are investing heavily in the technologies and expertise needed to develop these advanced formulations.Rising Demand for High-Potency APIs (HPAPIs)
With the growth of oncology and specialty drugs, OSD CDMOs are expanding their capabilities in handling HPAPIs safely and effectively.Digital Transformation and Automation
The adoption of smart manufacturing technologies, such as real-time monitoring and AI-driven process optimization, is helping CDMOs reduce errors, improve efficiency, and ensure batch-to-batch consistency.Regulatory Harmonization
Harmonized global standards and mutual recognition agreements between regulatory bodies (e.g., EMA and FDA) are easing the entry of CDMOs into new markets, fostering cross-border collaborations.Sustainability Initiatives
Environmental regulations and corporate responsibility goals are pushing CDMOs to adopt green chemistry practices and energy-efficient technologies in OSD manufacturing.
Conclusion
As the global pharmaceutical industry continues to evolve, the role of contract manufacturers—especially those specializing in oral solid dosage forms—has never been more critical. With a growing need for pharmaceutical outsourcing, increasing complexity in formulation development, and strict regulatory compliance requirements, the OSD contract manufacturing market is poised for sustained growth.
Companies that invest in innovation, capacity expansion, and regulatory excellence will lead the charge in transforming how drugs are manufactured and delivered across the globe. The next decade is expected to bring even greater collaboration between pharmaceutical firms and CDMOs, further reinforcing the essential role of oral solid dosage contract manufacturing in the global healthcare ecosystem.
More Trending Latest Reports By Polaris Market Research:
North America Flexible Foam Mold Release Agents Market
Intelligent Transport System Market
Comments
Post a Comment